Skip to content

Therapeutic vaccination for chronic hepatitis B virus infection in Africa

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN67270384
Enrollment
77
Registered
2005-11-23
Start date
2002-01-28
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B virus Infections and Infestations Hepatitis B virus

Interventions

This trial will take place in five parts: 1. An open label study in five healthy volunteers, of modified vaccinia virus Ankara (MVA.HBs) (a novel vaccine for HBV), then an open label non-randomised st

Sponsors

University of Oxford (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Chronic HBV infection 2. Male, 15 to 25 years 3. No evidence of liver inflammation or liver dysfunction

Exclusion criteria

Exclusion criteria: 1. Egg allergy 2. Serious disorder of any body system

Design outcomes

Primary

MeasureTime frame
1. Local tolerogenicity 2. Adverse events 3. Cellular immune responses to overlapping peptides of Hepatitis B surface protein 4. HBV serology 5. Anti-HBs levels, surface antigen 6. 'e' antigen 7. HBV viral load

Secondary

MeasureTime frame
No secondary outcome measures

Countries

Gambia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026